万古霉素

Search documents
新型抗生素有望持续对抗致命超级细菌
Ke Ji Ri Bao· 2025-09-22 00:10
英国利物浦大学科学家领衔的国际团队研制出一种名为Novltex的新型抗生素。测试表明,该抗生素对 多种致命超级细菌展现出持续抑制性,标志着对抗抗生素耐药性的努力取得重要进展。相关成果发表于 新一期《药物化学杂志》。 抗生素耐药性被列为人类面临的十大健康威胁之一,每年导致近500万人死亡。世界卫生组织发布的一 份急需新型抗生素的"优先病原体"名单,其中包括耐甲氧西林金黄色葡萄球菌和粪肠球菌。Novltex对 这两种细菌均表现出强效且快速的杀灭作用。 与传统抗生素不同,Novltex以脂质Ⅱ为靶点。脂质Ⅱ是细菌细胞壁的重要组成部分,不易发生突变。 这意味着Novltex可提供持久的耐药保护,有望应对现代医学中的一大难题。 团队此前曾开发出泰斯巴汀的简化合成版本。泰斯巴汀是从土壤细菌中分离出的一种环肽类抗生素,对 多种耐药菌具有显著活性。在此基础上,他们构建并测试了一个合成泰斯巴汀库,优化了多项关键性 能。 在最新研究中,受泰斯巴汀和另一种抗生素克洛维菌素启发,团队开发出新型抗生素Novltex。Novltex 避免了昂贵原料的使用,可用于构建大量候选分子以供优化,并靶向不易突变的脂质Ⅱ。这种高效、耐 用与可量产特 ...
大话集采:反内卷,请给条活路先!
Sou Hu Cai Jing· 2025-07-18 06:01
Core Viewpoint - The article discusses the impact of China's drug procurement policy on pharmaceutical companies, highlighting the shift from a price-cutting competition to a focus on quality and innovation in the industry [2][4][6]. Group 1: Price Competition and Its Consequences - The aggressive price competition in the pharmaceutical industry has led to significant revenue losses, with a total of 48.3 billion yuan cut from the national drug market after four rounds of procurement [2]. - The phenomenon of "price wars" has resulted in extremely low prices for drugs, exemplified by the 0.09 yuan per tablet price for Amlodipine, which is unsustainable for many companies [2][4]. - The intense competition has forced companies to compromise on quality, leading to concerns about supply disruptions and product quality [2][3]. Group 2: New Procurement Rules - The latest round of procurement introduces new rules aimed at curbing the "race to the bottom" in pricing, shifting the focus from "lowest price wins" to "value for money" [3][4]. - A new price difference mechanism has been established, allowing for reasonable price premiums, which requires companies to ensure that their quoted prices do not lead to losses [3][4]. - Quality standards have been tightened, with new regulations mandating that only companies with at least two years of production experience can participate, along with comprehensive inspections of both companies and products [3][4]. Group 3: Focus on Innovation - The new procurement policy allows for the exclusion of high-risk and patented drugs from the procurement process, enabling original branded drugs to compete in public hospitals if they agree to lower prices [4]. - The policy aims to facilitate a market environment where innovative drugs can thrive, with 60% of the savings from procurement being reinvested into innovative drug development [4][6]. - The shift from a focus on generic drugs to innovative solutions is seen as essential for the long-term sustainability of the pharmaceutical industry in China [6].
Nature子刊:华科谭磊/杨操团队开发超声增强的广谱抗菌肽,治疗抗生素耐药菌感染
生物世界· 2025-05-06 10:09
Core Viewpoint - The article discusses the development of a novel ultrasound-sensitive broad-spectrum antimicrobial peptide based on diphenylalanine, which shows high efficacy against drug-resistant bacteria and offers a promising strategy for treating infections caused by antibiotic-resistant pathogens [1][2][9]. Group 1: Antimicrobial Resistance and Challenges - Overuse of antibiotics has led to an increase in drug-resistant pathogens, making infections harder to treat and posing significant health risks globally [1]. - Traditional antimicrobial peptides (AMPs) have limitations, including slow antibacterial effects, rapid biodegradation, non-selective toxicity, and short retention time at infection sites [4]. Group 2: Research Findings - The research team developed a short peptide that is activated by ultrasound, achieving over 99% antibacterial efficiency against clinical isolates of methicillin-resistant bacteria within 15 minutes of ultrasound exposure, while exhibiting low toxicity [5][6]. - Seven short peptides were designed, with one specific peptide (FFRK8) demonstrating satisfactory antibacterial performance and biocompatibility under ultrasound activation [6]. Group 3: Clinical Implications - In a goat model of difficult-to-treat intervertebral disc infection, FFRK8 outperformed the potent antibiotic vancomycin, indicating its potential for clinical applications [7]. - The study suggests that ultrasound-activated antimicrobial peptides could provide an effective treatment for deep infections with poor vascular distribution, addressing the challenge of antibiotic resistance [9].